United States:
Janssen And Amgen Settle STELARA (Ustekinumab) BPCIA Litigation
26 May 2023
Goodwin Procter LLP
To print this article, all you need is to be registered or login on Mondaq.com.
We previously reported on Janssen's complaint
alleging that Amgen's filing of an aBLA for ustekinumab, a
biosimilar of STELARA, infringes Janssen patents, and about Janssen seeking a preliminary
injunction to block Amgen from the commercial
manufacturing, sale, and offer for sale of its ustekinumab product.
Briefing for the PI motion was to be completed by July 21, 2023,
and a hearing was scheduled for August 4, 2023. On May 22, 2023,
prior to the filing of Amgen's opposition brief in the
preliminary injunction proceedings (due the same day), Janssen and
Amgen filed a Stipulation and [Proposed] Order of Dismissal with
Prejudice indicating that the parties have agreed to
settle the litigation and dismiss the action with prejudice.
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
POPULAR ARTICLES ON: Intellectual Property from United States
Breaking Down The EPO's Revised Practice Guidelines
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
The guidelines for examination in the European Patent Office instruct on the practice and procedure related to the examination of European patent applications...
USPTO Embraces AI Tools In New Guidance
Crowell & Moring LLP
On April 11, 2024, the USPTO published its "Guidance on Use of Artificial Intelligence-Based Tools in Practice Before the United States" in the Federal Register (the "Guidance"). As the title suggests...
USPTO Issues Guidance On Use Of AI-Based Tools
Greenberg Traurig, LLP
On April 11, 2024, the U.S. Patent and Trademark Office (USPTO) issued Guidance on Use of Artificial-Intelligence-Based Tools (Guidance), which applies existing rules and policies...